Abstract
There are many different approaches to drug discovery in academia, some of which are based broadly on the industrial model of discovering novel targets and then conducting screening within academic drug discovery centres to identify hit molecules. Here we describe our approach to drug discovery, which makes more efficient use of the capabilities and resources of the different stakeholders. Specifically, we have created a large portfolio of drug projects and conducted small amounts of derisking work to ensure projects are investment ready. In this feature we will describe this model, including its limitations and advantages, since we believe the ideas and concepts will be of interest to other academic institutions and consortia.
| Original language | English |
|---|---|
| Article number | 103918 |
| Number of pages | 6 |
| Journal | Drug Discovery Today |
| Volume | 29 |
| Issue number | 4 |
| Early online date | 14 Feb 2024 |
| DOIs | |
| Publication status | Published - Apr 2024 |
Bibliographical note
Acknowledgements:This work was supported by the Wellcome Trust (204846/Z/16/Z) and by the University of Birmingham internal Dynamic Investment Fund. The authors would also like to acknowledge Professor Chris McCabe and Dr. Rowan Hardy at the University of Birmingham for their contribution to the case studies in this article.
Copyright:
© 2024 The Author(s). Published by Elsevier Ltd.
Keywords
- academic drug discovery
- drug development
- translation gap
- dynamic investment
- translational research
- prioritisation